Table 1 Clinical characteristics of patients switched to aflibercept from ranibizumab
From: Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD
Average number of intraocular injections before | 11.75±5.73 (6-25). |
Aflibercept injection (average-interval) | 3.44±0.73 (3-5) |
BCVA values (average /logMAR-ETDRS letters) | |
Before aflibercept injection | 1.08 (47.4 letters) |
After aflibercept injection | 0.80 (50 letters) |
Central macular thickness (average-interval) | |
Before aflibercept injection | 471.3 (97-1365) |
After aflibercept injection | 345.1 (97-585) |
The mean height of PED | |
Before aflibercept injection | 350.4 ± 151.7 (129-793) |
After aflibercept injection | 255.52 ± 156.8 (0-528) |